Clinical Characteristics of Rheumatic Diseases and Children Multisystem Inflammatory Syndrome Associated With COVID-19

With a new coronavirus infection, almost all organism systems are involved in the pathological process, which leads to development during the disease or post-COVID period of both new diseases and complications of existing chronic diseases requiring treatment or rehabilitation. The remaining after the suffered disease symptom complex complaints and clinical manifestations can be disturbed without conducting therapy and rehabilitation over many months. Purpose of the study. Present on their own observations of the laws of the clinical picture and therapies of the treatment of children’s multisystem inflammatory syndrome and systemic diseases of the connective tissue associated with COVID-19. Research results. Presented in Kyrgyzstan series of own clinical observations of 31 patients with children’s multisystem inflammatory syndrome and 23 patients with systemic diseases of the connective tissue associated with COVID-19, and 29 — with exacerbation of the systemic diseases of the connective tissue due to the transferred coronavirus infection, demonstrates the etiological and pathogeneic significance SARS COV2 in the emergence of a severe system of inflammatory response. Timely anti-inflammatory treatment of children’s multisystem inflammatory syndrome is crucial and must be adapted for each patient in order to achieve the most favorable effect. Patients of the systemic diseases of the connective tissue account for a risk group with regard to the disease COVID-19 and the unfavorable disease.